2Bertrand Baujat,Hélène Audry,Jean Bourhis,Anthony T.C. Chan,Haluk Onat,Daniel T.T. Chua,Dora L.W. Kwong,Muhyi al-Sarraf,Kwan-Hwa Chi,Masato Hareyama,Sing F. Leung,Kullathorn Thephamongkhol,Jean-Pierre Pignon.Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients[J]. International Journal of Radiation Oncology, Biology, Physics . 2006 (1)
3Maureen Trudeau,Flay Charbonneau,Karen Gelmon,Kara Laing,Jean Latreille,John Mackey,Deanna McLeod,Kathy Pritchard,Louise Provencher,Shailendra Verma.Selection of adjuvant chemotherapy for treatment of node-positive breast cancer[J]. Lancet Oncology . 2005 (11)
4Reitsamer Roland,Peintinger Florentia,Prokop Eva,Hitzl Wolfgang.Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anti Cancer Drugs . 2005
5Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CACancer J Clin, 2011, 61(2): 69-90.
6Beresford MJ, Harris AL, Ah-See M, et al. The relationship of theneoangiogenic marker, endoglin, with response to neoadjuvantchemotherapy in breast cancer[J]. Br J Cancer, 2006, 95(12):1683-1688.
7Bear HD, Anderson S, Brown A, et al. The effect on tumor responseof adding sequential preoperative docetaxel to preoperativedxorubincin and cyclophosphamide: preliminary results fromNational Surgical Adjuvant Breast and Bowel Project protocolB-27[J]. J Clin Oncol, 2003, 21(22): 4165-4174.
8Espinosa E, Morales S, Borrega P, et al. Docetaxel and high-doseepirubicin as neoadjuvant chemotherapy in locally advanced breastcancer[J]. Cancer Chemother Pharmacol, 2004, 54(6): 546-552.
